Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable

2.1 Atezolizumab (Tecentriq, Roche) as a monotherapy is indicated for 'the treatment of adult patients with locally advanced or metastatic urothelial cancer who are considered cisplatin ineligible, and whose tumours have a PD‑L1 expression of 5% or more'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price is £3,807.69 per 1,200‑mg vial (excluding VAT; BNF online, accessed August 2021), which is an annual cost of around £66,000. The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.